Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by mcarter4on Sep 25, 2003 1:01pm
248 Views
Post# 6459135

RE: Wow - lot's of reading. Thoughts.

RE: Wow - lot's of reading. Thoughts.The specific concern I have is this: ONC mngt. has indicated 2yrs of cash on hand for the business after previous recent financings. The need for the $5M has no apparent basis in the business plan as expressed recently by mngt. Therefore, to me more funding should have waited until an update on trials, and then a higher price, less shares, etc. Someone yesterday indicated the deal was opportunistically presented to mngt who bit. This makes me nervous about management capability, resolve and belief in their business. Their science may be great but management can really screw up deriving maximum value (which I believe this may be a case of). I've always thought the weak link in ONC is mngt and BOD (too Alberta), although the Advisory Board was a great move.
Bullboard Posts